J. Bothos

发表

Defective in Mitotic Arrest 1/Ring Finger 8 Is a Checkpoint Protein That Antagonizes the Human Mitotic Exit Network

Thanos D Halazonetis, T. Halazonetis, F. Luca, 2007, Molecular Cancer Research.

The Chfr mitotic checkpoint protein functions with Ubc13-Mms2 to form Lys63-linked polyubiquitin chains

T. Halazonetis, M. Venere, J. Bothos, 2003, Oncogene.

Human LATS1 is a mitotic exit network kinase.

T. Halazonetis, F. Luca, R. L. Tuttle, 2005, Cancer research.

The CHFR mitotic checkpoint protein delays cell cycle progression by excluding Cyclin B1 from the nucleus

T. Halazonetis, J. Bothos, M. Summers, 2005, Oncogene.

Abstract 2774: Complete results from a phase Ia dose-escalation and dose-expansion study of single-agent MetMAb, a monovalent antagonist antibody to the receptor MET, administered intravenously in patients with locally advanced or metastatic solid tumors

P. Hegde, M. Ratain, R. Salgia, 2010 .

COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer

R. Herbst, S. Dakhil, D. Camidge, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide

D. Petrylak, M. Fleming, R. Cathomas, 2021, Clinical Cancer Research.

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

Nibedita Bandyopadhyay, Martin Dreyling, Mathias Witzens-Harig, 2016, The Lancet.

Crystal structure of a human Mob1 protein: toward understanding Mob-regulated cell cycle pathways.

P. Jeffrey, N. Pavletich, E. Stavridi, 2003, Structure.

MEDI3726, a prostate-specific membrane antigen (PSMA)-targeted antibody-drug conjugate (ADC) in mCRPC after failure of abiraterone or enzalutamide.

M. Fleming, D. Petrylak, R. Cathomas, 2020 .

Safety data and patterns of progression in met diagnostic subgroups in OAM4558g; A phase II trial evaluating MetMAb in combination with erlotinib in advanced NSCLC.

J. Bothos, D. Spigel, J. Goldschmidt, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies

P. Hegde, M. Ratain, R. Salgia, 2014, Clinical Cancer Research.

Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors

John D. Davis, J. Bothos, I. Nijem, 2013, Journal of clinical pharmacology.

Inactivating mutations targeting the chfr mitotic checkpoint gene in human lung cancer.

T. Halazonetis, V. Gorgoulis, C. Kittas, 2003, Cancer research.

LBA42 COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC

R. Herbst, D. Camidge, F. Barlesi, 2021, Annals of Oncology.

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

J. Goldberg, M. Jerkeman, M. Dreyling, 2016, The Lancet.